Effect of Insulin Degludec Versus Insulin Glargine U100 on Hypoglycemia in Hispanic Patients With Type 2 Diabetes: Results From the SWITCH 2 Trial

por Chaykin, Louis, Bhargava, Anuj, de la Rosa, Raymond, Wysham, Carol H., Nørgård Troelsen, Lone, Østoft, Signe H., Philis-Tsimikas, Athena
Publicado 2019

Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events

por Lingvay, Ildiko, Hansen, Thomas, Macura, Stanislava, Marre, Michel, Nauck, Michael A, de la Rosa, Raymond, Woo, Vincent, Yildirim, Emre, Wilding, John
Publicado 2020

Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial

por Rodbard, Helena W, Lingvay, Ildiko, Reed, John, de la Rosa, Raymond, Rose, Ludger, Sugimoto, Danny, Araki, Eiichi, Chu, Pei-Ling, Wijayasinghe, Nelun, Norwood, Paul
Publicado 2018